<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943809</url>
  </required_header>
  <id_info>
    <org_study_id>Poyales/POD FT - POD F</org_study_id>
    <nct_id>NCT04943809</nct_id>
  </id_info>
  <brief_title>Comparison of Visual Outcomes After Implantation of the POD FT and the POD F</brief_title>
  <acronym>PoyPODF/FT</acronym>
  <official_title>Comparison of Visual Outcomes After Implantation of the POD 26P AY FT (PhysIOL) and the POD 26P AY F (PhysIOL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beaver-Visitec International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beaver-Visitec International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no difference of the photic phenomena in the two groups.&#xD;
&#xD;
      The study will be a prospective non-randomised controlled study. The target is then to&#xD;
      determine the equivalence in the glare. Assumption of Type I error is p=0.05 as level of&#xD;
      significance and Type II error is alpha=0.8 as power.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a prospective non-randomised controlled study. The target is then to&#xD;
      determine the equivalence in the glare. Assumption of Type I error is p=0.05 as level of&#xD;
      significance and Type II error is alpha=0.8 as power.&#xD;
&#xD;
      We used the 'TrialSize' package of the R software. Here are the parameters defined for the&#xD;
      sample size calculation:&#xD;
&#xD;
        1. Alpha: 0.05&#xD;
&#xD;
        2. Power : 0.90&#xD;
&#xD;
        3. Two sided test&#xD;
&#xD;
        4. Equal group allocation&#xD;
&#xD;
        5. Standard deviation for the two groups (POD 26P AY F et POD 26P AY FT) equal to 0.10&#xD;
&#xD;
        6. Expected mean for the two groups (POD 26P AY F et POD 26P AY FT) equal to 0.89 (true&#xD;
           difference between the means equal 0)&#xD;
&#xD;
        7. An equivalence limit of 0.05, 0.10 and 0.15 Equivalence limit: 0.15 In order to show no&#xD;
           difference between these two groups, 12 patients by groups are needed. With a drop-out&#xD;
           of 15%, we obtain 30 patients (15 patients by group) to recruit in order to obtain 24&#xD;
           valuable patients.&#xD;
&#xD;
      Equivalence limit: 0.10 In order to show no difference between these two groups, 26 patients&#xD;
      by groups are needed. With a drop-out of 15%, we obtain 62 patients (31 patients by group) to&#xD;
      recruit in order to obtain 52 valuable patients.&#xD;
&#xD;
      This total number of subjects with such requirement is 26 patients in each group.&#xD;
&#xD;
      Group 1 will be made of 26 patients with corneal astigmatism higher than 1.0D in both eyes&#xD;
      and lower than 2.5D and will be implanted with the POD 26P AY FT and Group 2 will be made of&#xD;
      26 patients with corneal astigmatism lower than 1.0D in both eyes.&#xD;
&#xD;
      Interim analysis after the 12th patient of each group will have completed the last follow-up&#xD;
      will be achieved to confirm the equivalence with the equivalence limit of 0.15.&#xD;
&#xD;
      The POD platform in 26 % (non toric version) is available since 2008 in the monofocal version&#xD;
      and since 2012 in the toric one (POD 6P AY T, Ankoris®, PhysIOL).The so-called POD design is&#xD;
      characterised by two symmetrical bifid haptics with opened loops that provide four points of&#xD;
      support to ensure IOL stability in the capsular bag. The dual C-loop profile shortens the&#xD;
      loops, thus improving the pliability of the implant during its injection through a&#xD;
      micro-incision. These shortened loops should permit a clockwise or anticlockwise rotary&#xD;
      motion and should facilitate the comfortable fitting of the implant orientation after&#xD;
      unfolding without elastic-restoring torque. The double C-loop POD design offers 4 support&#xD;
      points for the implant within the capsule and ensures its stability. The V-shape of the upper&#xD;
      and lower haptics together with the flexibility of the implant allow the loop separation&#xD;
      angle to be adjusted and ensure the most accurate adaptation to the capsular bag size. A&#xD;
      finite element structural analysis of the implant showed that the elasticity at the distal&#xD;
      part of the loop prevents the constraints from being transmitted onto the optical portion of&#xD;
      the implant. The trifocal optic is associated to the POD platform and is made of 26 % raw&#xD;
      material.&#xD;
&#xD;
      The rotational stability of this non toric version has been clinically investigated on 117&#xD;
      consecutive eyes 1 week, 3 weeks, 3 and 12 months after implantation. The absolute rotation&#xD;
      of the lens averaged 2.5 ± 2.6°. The position of the center of the implant relative to the&#xD;
      pupillary center expressed by a vector was 0.01 mm at 70°.&#xD;
&#xD;
      The investigational product (POD 26P AY FT) is CE labeled since January 2014. Main IOL&#xD;
      features are:&#xD;
&#xD;
        -  Biconvex toric aspheric (-0.11um SA) blue-blocking, hydrophilic acrylic IOL with 26%&#xD;
           equlibrium water content, implantable through ≥ 2.2mm incision.&#xD;
&#xD;
        -  4-point haptic design&#xD;
&#xD;
        -  6 mm of optical diameter / 11.4 mm of total diameter&#xD;
&#xD;
        -  Dioptric range (SE): 6 to 35 D by 0.5 D increments&#xD;
&#xD;
        -  Cylinders at the IOL plane: 1, 1.5, 2.25, 3, 3.75, 4.5, 5.25, 6 D&#xD;
&#xD;
        -  Addition +1.75D / +3.5 D&#xD;
&#xD;
      The control product (POD 26P AY F) is CE labeled since 2010. Main IOL features are:&#xD;
&#xD;
        -  Biconvex, aspheric (-0.11um SA) blue-blocking, hydrophilic acrylic IOL with 26%&#xD;
           equlibrium water content, implantable through ≥ 2.2mm incision.&#xD;
&#xD;
        -  4-point haptics design which minimizes decentration and optimizes the rotational&#xD;
           stability&#xD;
&#xD;
        -  6 mm of optical diameter / 11.4 mm of total diameter&#xD;
&#xD;
        -  Dioptric range (SE): 6 to 35 D by 0.5 D increments&#xD;
&#xD;
        -  Addition +1.75D / +3.5 D&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2014</start_date>
  <completion_date type="Actual">July 20, 2017</completion_date>
  <primary_completion_date type="Actual">July 20, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the equivalence of the glare</measure>
    <time_frame>3 Months</time_frame>
    <description>The primary endpoint is to show statistically equivalent outcomes on glare at the 3 months follow up visit. A significance level of p = 0.05 will be considered statistically significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of far, intermediate and near visual acuity</measure>
    <time_frame>6 Months</time_frame>
    <description>The secondary objective is to measure far, intermediate and near visual acuity of the POD AY 26P FT with respect to the POD AY 26P F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Refraction</measure>
    <time_frame>6 Months</time_frame>
    <description>The secondary objective is to measure the refraction of the POD AY 26P FT with respect to the POD AY 26P F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Centration</measure>
    <time_frame>6 Months</time_frame>
    <description>The secondary objective is to measure the centration of the POD AY 26P FT with respect to the POD AY 26P F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rotational stability</measure>
    <time_frame>6 Months</time_frame>
    <description>The secondary objective is to measure the rotational stability of the POD AY 26P FT with respect to the POD AY 26P F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Equivalence of the visual acuity and the contrast sensitivity</measure>
    <time_frame>6 Months</time_frame>
    <description>The secondary objective is to determine the equivalence of the visual acuity of the POD AY 26P FT with respect to the POD AY 26P F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Equivalence of the visual acuity and the contrast sensitivity</measure>
    <time_frame>6 Months</time_frame>
    <description>The secondary objective is to determine the contrast sensitivity at far of the POD AY 26P FT with respect to the POD AY 26P F.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">63</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>POD 26P AY FT</arm_group_label>
    <description>26 patients with corneal astigmatism higher than 1.0D in both eyes and lower than 2.5D and will be implanted with the POD 26P AY FT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POD 26P AY F</arm_group_label>
    <description>26 patients with corneal astigmatism lower than 1.0D in both eyes will be implanted with the POD 26P AY F</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>POD 26P AY FT</intervention_name>
    <description>Routine cataract surgery</description>
    <arm_group_label>POD 26P AY FT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>POD 26P AY F</intervention_name>
    <description>Routine cataract surgery</description>
    <arm_group_label>POD 26P AY F</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of patients undergoing routine cataract surgery. The study&#xD;
        participants receive a bilateral implantation of trifocal intraocular lenses. Depending on&#xD;
        the preoperative corneal astigmatism, the patients receive either non-toric trifocal IOLs&#xD;
        (POD F) or toric trifocal IOLs (POD FT) in both eyes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age-related cataract&#xD;
&#xD;
          -  Preoperative Corneal astigmatism &lt; 0.75 D&#xD;
&#xD;
          -  Age 21 and older&#xD;
&#xD;
          -  Visual Acuity &gt; 0.05&#xD;
&#xD;
          -  Normal findings in the medical history and physical examination unless the&#xD;
             investigator considers an abnormality to be clinically irrelevant.&#xD;
&#xD;
          -  Patient willing multifocal implantation and with realistic expectations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relevant other ophthalmic diseases such as pseudoexfoliation syndrome, floppy iris&#xD;
             syndrome, corneal pathologies, retinal pathology (diabetic maculopathy, myopic&#xD;
             maculopathy, age related macular degeneration...)&#xD;
&#xD;
          -  Previous ocular surgery or trauma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Poyales Galan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEIC Hospital Clinical San Carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Chassain C, Pagnoulle C, Gobin L, Rozema J. [Evaluation of a new intraocular lens platform: centration and rotational stability]. J Fr Ophtalmol. 2013 Apr;36(4):336-42. doi: 10.1016/j.jfo.2012.04.012. Epub 2013 Jan 24. French.</citation>
    <PMID>23352708</PMID>
  </reference>
  <results_reference>
    <citation>Visser N, Bauer NJ, Nuijts RM. Toric intraocular lenses: historical overview, patient selection, IOL calculation, surgical techniques, clinical outcomes, and complications. J Cataract Refract Surg. 2013 Apr;39(4):624-37. doi: 10.1016/j.jcrs.2013.02.020. Review.</citation>
    <PMID>23522584</PMID>
  </results_reference>
  <results_reference>
    <citation>de Vries NE, Nuijts RM. Multifocal intraocular lenses in cataract surgery: literature review of benefits and side effects. J Cataract Refract Surg. 2013 Feb;39(2):268-78. doi: 10.1016/j.jcrs.2012.12.002. Review.</citation>
    <PMID>23332253</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolffsohn JS, Jinabhai AN, Kingsnorth A, Sheppard AL, Naroo SA, Shah S, Buckhurst P, Hall LA, Young G. Exploring the optimum step size for defocus curves. J Cataract Refract Surg. 2013 Jun;39(6):873-80. doi: 10.1016/j.jcrs.2013.01.031.</citation>
    <PMID>23688874</PMID>
  </results_reference>
  <results_reference>
    <citation>Sheppard AL, Shah S, Bhatt U, Bhogal G, Wolffsohn JS. Visual outcomes and subjective experience after bilateral implantation of a new diffractive trifocal intraocular lens. J Cataract Refract Surg. 2013 Mar;39(3):343-9. doi: 10.1016/j.jcrs.2012.09.017. Epub 2013 Jan 16.</citation>
    <PMID>23332118</PMID>
  </results_reference>
  <results_reference>
    <citation>Cochener B, Vryghem J, Rozot P, Lesieur G, Heireman S, Blanckaert JA, Van Acker E, Ghekiere S. Visual and refractive outcomes after implantation of a fully diffractive trifocal lens. Clin Ophthalmol. 2012;6:1421-7. doi: 10.2147/OPTH.S32343. Epub 2012 Sep 3.</citation>
    <PMID>22969289</PMID>
  </results_reference>
  <results_reference>
    <citation>Roensch MA, Charton JW, Blomquist PH, Aggarwal NK, McCulley JP. Resident experience with toric and multifocal intraocular lenses in a public county hospital system. J Cataract Refract Surg. 2012 May;38(5):793-8. doi: 10.1016/j.jcrs.2011.11.043. Epub 2012 Mar 15.</citation>
    <PMID>22425363</PMID>
  </results_reference>
  <results_reference>
    <citation>Visser N, Nuijts RM, de Vries NE, Bauer NJ. Visual outcomes and patient satisfaction after cataract surgery with toric multifocal intraocular lens implantation. J Cataract Refract Surg. 2011 Nov;37(11):2034-42. doi: 10.1016/j.jcrs.2011.05.041. Epub 2011 Sep 22.</citation>
    <PMID>21940140</PMID>
  </results_reference>
  <results_reference>
    <citation>Bellucci R, Bauer NJ, Daya SM, Visser N, Santin G, Cargnoni M, Nuijts RM; Lisa Toric Study Group. Visual acuity and refraction with a diffractive multifocal toric intraocular lens. J Cataract Refract Surg. 2013 Oct;39(10):1507-18. doi: 10.1016/j.jcrs.2013.04.036.</citation>
    <PMID>24075158</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso JF, Knorz M, Fernandez-Vega L, Rincón JL, Suarez E, Titke C, Kohnen T. Clinical outcomes after bilateral implantation of an apodized +3.0 D toric diffractive multifocal intraocular lens. J Cataract Refract Surg. 2014 Jan;40(1):51-9. doi: 10.1016/j.jcrs.2013.06.026.</citation>
    <PMID>24355720</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferreira TB, Marques EF, Rodrigues A, Montés-Micó R. Visual and optical outcomes of a diffractive multifocal toric intraocular lens. J Cataract Refract Surg. 2013 Jul;39(7):1029-35. doi: 10.1016/j.jcrs.2013.02.037. Epub 2013 May 13.</citation>
    <PMID>23680631</PMID>
  </results_reference>
  <results_reference>
    <citation>Knorz MC, Rincón JL, Suarez E, Alfonso JF, Fernández-Vega L, Titke C, Kohnen T, Tucker S. Subjective outcomes after bilateral implantation of an apodized diffractive +3.0 D multifocal toric IOL in a prospective clinical study. J Refract Surg. 2013 Nov;29(11):762-7. doi: 10.3928/1081597X-20131021-06.</citation>
    <PMID>24203808</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hydrophilic</keyword>
  <keyword>Toric</keyword>
  <keyword>intraocular lens</keyword>
  <keyword>cataract</keyword>
  <keyword>trifocal</keyword>
  <keyword>BVI Medical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

